Cargando…

Successful use of prolonged cefiderocol monotherapy for the treatment of a complex pleural abscess caused by extensively drug-resistant (XDR) Pseudomonas aeruginosa

Detalles Bibliográficos
Autores principales:	Brookfield, Charlotte, Fadden, Emma, Sweeney, Louise
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481248/ https://www.ncbi.nlm.nih.gov/pubmed/37680881 http://dx.doi.org/10.1093/jacamr/dlad103

Ejemplares similares

Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa
por: Chavda, A, et al.
Publicado: (2021)

Cefiderocol is an effective topical monotherapy for experimental extensively-drug resistant Pseudomonas aeruginosa keratitis
por: Romanowski, Eric G., et al.
Publicado: (2023)

P44 Nosocomial neurosurgical meningitis due to XDR Pseudomonas aeruginosa: clinical experience with cefiderocol
por: Stevenson, D. R., et al.
Publicado: (2022)

Molecular Evolution of Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa Strains From Patients and Hospital Environment in a Prolonged Outbreak
por: Buhl, Michael, et al.
Publicado: (2019)

Successful prolonged cefiderocol treatment of a chronic left pleural empyema caused by Pseudomonas aeruginosa in a patient affected by COVID-19: a case report
por: Borghesi, Luca, et al.
Publicado: (2021)

ATP Bioluminescence Assay To Evaluate Antibiotic Combinations against Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa
por: Puig-Collderram, Berta, et al.
Publicado: (2022)

Development and Evaluation of Bacteriophage Cocktail to Eradicate Biofilms Formed by an Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa
por: Vashisth, Medhavi, et al.
Publicado: (2023)

XDR-Pseudomonas aeruginosa Outside the ICU: Is There Still Place for Colistin?
por: Del Giacomo, Paola, et al.
Publicado: (2022)

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019
por: Karlowsky, James A., et al.
Publicado: (2022)

Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa
por: Sadek, Mustafa, et al.
Publicado: (2022)

Combination of phage therapy and cefiderocol to successfully treat Pseudomonas aeruginosa cranial osteomyelitis
por: Simner, Patricia J., et al.
Publicado: (2022)

Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of Pseudomonas aeruginosa
por: Kothari, Ashish, et al.
Publicado: (2023)

Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations
por: Kufel, Wesley D., et al.
Publicado: (2020)

223. Clinical Characteristics and Outcomes of Acinetobacter baumannii XDR and Pseudomonas aeruginosa XDR in a Tertiary Referral Medical Center in Mexico
por: Ojeda Yuren, Alicia Sarahi, et al.
Publicado: (2023)

XDR-TB in South Africa: Revised Definition
por: Holtz, Timothy H
Publicado: (2007)

XDR-TB in South Africa: Detention Is Not the Priority
por: Goemaere, Eric, et al.
Publicado: (2007)

XDR-TB in South Africa: Theory and Practice
por: Andrews, Jason, et al.
Publicado: (2007)

Use of Ceftolozane-Tazobactam in Patient with Severe Medium Chronic Purulent Otitis by XDR Pseudomonas aeruginosa
por: Saraca, L. M., et al.
Publicado: (2019)

XDR-TB in South Africa: Back to TB Sanatoria Perhaps?
por: Sakoane, Ramalitse
Publicado: (2007)

WHO's Response to Global Public Health Threats: XDR-TB
por: Wilson, Kumanan, et al.
Publicado: (2007)

Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2021)

2453. Prolonged Local Epidemic of an XDR P. aeruginosa Subclade of High-Risk Clonal Complex 298
por: Pincus, Nathan B, et al.
Publicado: (2019)

Interplay between mutational and horizontally acquired resistance mechanisms and its association with carbapenem resistance amongst extensively drug-resistant Pseudomonas aeruginosa (XDR-PA)
por: Shu, Jwu-Ching, et al.
Publicado: (2012)

648. Cefiderocol as Rescue Therapy for Pseudomonas aeruginosa and Other Difficult-To-Treat Gram-Negative Infections
por: Chou, Andrew, et al.
Publicado: (2022)

Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program
por: Satlin, Michael J., et al.
Publicado: (2023)

2750. Pseudomonas aeruginosa infections treated with cefiderocol: associations of site of infection and time to first dose with outcomes in PROVE (Retrospective Cefiderocol Chart Review) Study
por: Marcella, Stephen, et al.
Publicado: (2023)

Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from Northeast of Iran
por: Mirzaei, Bahman, et al.
Publicado: (2020)

Risk Factors for Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: What Is the Influence of XDR Phenotype on Outcomes?
por: Montero, María Milagro, et al.
Publicado: (2020)

Extensive Discoid Lupus Erythematosus in a HIV patient Responding to Hydroxychloroquine Monotherapy
por: Bhagwat, Pradeep Vittal, et al.
Publicado: (2012)

Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa
por: Ito, Akinobu, et al.
Publicado: (2016)

Ceftolozane-tazobactam and Fosfomycin for rescue treatment of otogenous meningitis caused by XDR Pseudomonas aeruginosa: Case report and review of the literature
por: Frattari, Antonella, et al.
Publicado: (2018)

Virulence factors and integrons are associated with MDR and XDR phenotypes in nosocomial strains of Pseudomonas aeruginosa in a Venezuelan university hospital
por: Rodulfo, Hectorina, et al.
Publicado: (2019)

1458. Uncharted territories: applying “precision medicine” to understand the treacherous landscape of extensively and multidrug resistant (XDR and MDR) Pseudomonas aeruginosa in a patient with cystic fibrosis and lung transplantation
por: Rojas, Laura J, et al.
Publicado: (2020)

Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City
por: Iregui, Alejandro, et al.
Publicado: (2020)

Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections
por: Meschiari, Marianna, et al.
Publicado: (2021)

Erratum to: Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction; Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice; Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa; Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection; Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
Publicado: (2021)

Cure of Limb-Threatening XDR Pseudomonas aeruginosa Infection: Combining Genome Sequencing, Therapeutic Drug Level Monitoring, and Surgical Debridement
por: Narayanasamy, Shanti, et al.
Publicado: (2020)

Two artificial tears outbreak-associated cases of XDR Pseudomonas aeruginosa detected through whole genome sequencing-based surveillance
por: Sundermann, Alexander J., et al.
Publicado: (2023)

635. Genomic Evolution and Progression of Antimicrobial Resistance in a Series of Extensively Drug-Resistant Pseudomonas aeruginosa (XDR-Pa) Isolates from a Cystic Fibrosis Lung Transplant Recipient
por: Yasmin, Mohamad, et al.
Publicado: (2019)

Methylprednisolone: Pseudomonas aeruginosa lung abscess: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9filv8k67qpah13f9k17kdo0ub